Omada Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$7.9
Valuation models combined (3)
Base case. Range ~$5.1–$9.8. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers), the growth cash-flow model counting double.
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Omada Health, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $310m. Free-cash-flow margin rose to 7.3% from -9.3% a year earlier. Operating margin widened to -0.1% from -13.5%. It passes 2 of our 3 financial-health checks.
Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Omada Health, Inc.'s trailing-twelve-month revenue grew 47.6% year on year, with a free-cash-flow margin of 7.3%.
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 220% in the quarter to 2026-06-30, the 4th beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Omada Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.74 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$7.7 ~$6.2–$9.0 | Primary model, counts double |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$9.8 ~$8.0–$14 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$5.1 ~$5.1–$14 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$7.9 ~$5.1–$9.8 | 3 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Omada Health, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2025 |
|---|---|
| Share price | $15.78 |
| Market value | $578m |
| + Net debt (− = net cash) | −$222m |
| Enterprise value | $356m |
| Multiples | |
| Price / sales | 2.2x |
| Price / earnings | — |
| Price / free cash flow | 34.2x |
| EV / EBITDA | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 5, 2026, after the close. Analysts expect revenue of $86m and EPS of $0.10 (range $0.08 to $0.12) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $0.44 | +182% | $339m | +30% |
| Next | $0.56 | +28% | $408m | +20% |
Next year's EPS estimate has moved +17.4% in 90 days, across 5 analysts.
The consensus EPS forecast for the current fiscal year is +38.9% on 90 days ago. In the last 30 days, 5 analysts raised Omada Health, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $0.31 | $0.47 |
| 60 days ago | $0.44 | $0.56 |
| 30 days ago | $0.44 | $0.56 |
| 7 days ago | $0.44 | $0.56 |
| Now | $0.44 | $0.56 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.06 | $0.20 | +219.8% |
| Mar 2026 | −$0.04 | $0.05 | +209.9% |
| Dec 2025 | $0.03 | $0.16 | +440.3% |
| Sept 2025 | −$0.07 | $0.03 | +142.6% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2026 to date |
|---|---|
| Return | |
| OMDA | +13% |
| Industry peers (median) | +15% |
| S&P 500 | +11% |
| Months that ended higher | |
| OMDA | 46% |
| S&P 500 | 46% |
| Largest fall from a high during the year | |
| OMDA | −34% |
| S&P 500 | −9% |
Worst fall since June 6, 2025: 59% from October 28, 2025 to February 11, 2026. Getting back needed a 145% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | +23.9% | +0.5% | +27.5% | +19.2% |
| May 7, 2026 | −6.6% | +0.5% | +4.5% | +12.7% |
| March 5, 2026 | +3.9% | −1.9% | +3.7% | −7.0% |
| January 12, 2026 | +4.7% | 0.0% | +2.1% | −29.0% |
| November 6, 2025 | −12.8% | −1.0% | −10.9% | −32.8% |
| August 7, 2025 | −2.2% | +0.7% | +5.0% | +23.6% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY25 Q1 | $189.7M |
| FY25 Q2 | $209.8M |
| FY25 Q3 | $232.3M |
| FY25 Q4 | $260.2M |
| FY26 Q1 | $283.3M |
| FY26 Q2 | $309.8M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY25 Q1 | -18.0% |
| FY25 Q2 | -13.5% |
| FY25 Q3 | -9.6% |
| FY25 Q4 | -4.6% |
| FY26 Q1 | -2.9% |
| FY26 Q2 | -0.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY25 Q2 | -9.3% |
| FY25 Q3 | -4.7% |
| FY25 Q4 | 6.5% |
| FY26 Q1 | 7.6% |
| FY26 Q2 | 7.3% |
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 123 | 170 | 260 | 310 |
| Gross profit | 70 | 103 | 171 | 211 |
| EBITDA | −62 | −39 | −6 | 5 |
| Operating income | −66 | −44 | −12 | −0 |
| Net income | −68 | −47 | −13 | 4 |
| Diluted EPS | −$1.90 | −$1.22 | −$0.35 | — |
| Growth (year on year) | ||||
| Revenue | — | +38.3% | +53.2% | +47.6% |
| Margins | ||||
| Gross margin | 57.0% | 60.6% | 65.7% | 68.2% |
| EBITDA margin | −50.1% | −22.9% | −2.5% | 1.8% |
| Operating margin | −53.8% | −25.7% | −4.6% | −0.1% |
| Net margin | −55.0% | −27.8% | −4.9% | 1.4% |
| Free-cash-flow margin | −40.8% | −20.5% | 6.5% | 7.3% |
| Cash flow | ||||
| Cash from operations | −50 | −34 | 18 | 24 |
| Capital spending | 0 | 1 | 1 | 1 |
| Free cash flow | −50 | −35 | 17 | 23 |
| Stock-based pay | 9 | 9 | 13 | 17 |
| Free cash flow after stock pay | −59 | −44 | 4 | 6 |
| Balance sheet | ||||
| Cash | 116 | 76 | 222 | 222 |
| Total debt | 0 | 30 | 0 | 0 |
| Net debt (negative = net cash) | −116 | −47 | −222 | −222 |
| Diluted shares | 35m | 39m | 37m | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 46 | 48 | 55 | 61 | 68 | 76 | 78 | 88 |
| Gross profit | 29 | 32 | 32 | 40 | 45 | 54 | 49 | 64 |
| EBITDA | −7 | −6 | −7 | −3 | −1 | 5 | −3 | 5 |
| Operating income | −9 | −7 | −8 | −4 | −3 | 3 | −5 | 4 |
| Net income | −9 | −8 | −9 | −5 | −3 | 5 | −3 | 5 |
| Diluted EPS | −$1.18 | −$1.02 | −$1.15 | −$0.24 | −$0.06 | $0.26 | −$0.05 | $0.08 |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | +48.9% | +49.5% | +58.1% | +42.0% | +43.1% |
| Margins | ||||||||
| Gross margin | 62.8% | 67.0% | 58.0% | 65.7% | 66.3% | 70.8% | 62.4% | 72.6% |
| EBITDA margin | −16.0% | −12.1% | −12.9% | −4.9% | −1.7% | 6.2% | −4.2% | 5.8% |
| Operating margin | −18.7% | −14.8% | −15.3% | −7.1% | −3.7% | 4.3% | −6.1% | 4.0% |
| Net margin | −20.3% | −17.2% | −17.2% | −8.7% | −4.7% | 6.8% | −3.8% | 6.0% |
| Free-cash-flow margin | 2.2% | −13.9% | −29.9% | 4.2% | 14.1% | 27.9% | −15.3% | 4.4% |
| Cash flow | ||||||||
| Cash from operations | 1 | −6 | −16 | 3 | 10 | 21 | −12 | 4 |
| Capital spending | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Free cash flow | 1 | −7 | −16 | 3 | 10 | 21 | −12 | 4 |
| Stock-based pay | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 6 |
| Free cash flow after stock pay | −1 | −9 | −19 | −0 | 6 | 17 | −16 | −2 |
| Last 12 months unless stated | OMDA | VMD | DCGO | DLHC | CDNA | SBC | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $310m | $302m | $295m | $254m | $497m | $175m | $1.1bn |
| Revenue growth, last 12 months | 47.6% | 25.2% | −32.4% | −29.5% | 38.9% | −6.9% | 7.4% |
| Revenue growth, 3-year average | — | 24.5% | −13.3% | −9.5% | 18.7% | — | 11.3% |
| Revenue growth, latest quarter | 43.1% | 23.9% | −8.7% | −46.9% | 39.3% | 13.4% | 8.6% |
| Gross margin | 68.2% | 57.5% | — | 24.3% | 65.5% | 71.9% | 27.9% |
| Operating margin | −0.1% | 7.5% | −62.2% | −0.1% | 23.4% | 37.3% | 2.0% |
| Operating margin, 3-year average | — | 7.9% | −20.8% | 3.5% | −4.4% | 37.3% | 2.3% |
| Net margin | 1.4% | 4.8% | −65.3% | −8.5% | 25.9% | 28.0% | 1.2% |
| Cash from operations / revenue | 7.6% | 20.2% | −7.7% | 5.5% | 13.9% | 35.9% | 6.3% |
| Free-cash-flow margin | 7.3% | 9.7% | −8.8% | 5.5% | 10.3% | 35.3% | 5.2% |
| Free-cash-flow margin, 3-year average | — | 4.1% | 1.4% | 6.6% | 5.3% | — | 3.6% |
| Stock pay / revenue | 5.5% | 3.0% | 4.6% | 0.5% | 7.7% | — | 1.1% |
| Change in share count | — | −1.6% | −7.1% | 2.2% | −9.3% | 1.4% | 0.3% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Services | $241M | 92.6% | ▲ 52.8% |
| Hardware | $19.2M | 7.4% | ▲ 59.6% |
From Omada Health, Inc.'s 10-K filed March 6, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Revelation Capital Management, LLC | $107M | 4.9M | 9.2% | ▼ 6.7% |
| Divisadero Street Capital Management, LP | $83.4M | 3.8M | 7.2% | ▼ 35.5% |
| American Century Companies Inc | $80.7M | 3.7M | 7.0% | ▲ 49.8% |
| Cigna Investments Inc | $75.6M | 3.4M | 6.6% | 0.0% |
| Morgan Stanley | $61.5M | 2.8M | 5.3% | ▲ 91.0% |
| FMR LLC | $60.9M | 2.8M | 5.3% | ▼ 15.6% |
| Nvp Associates, LLC | $55.6M | 2.5M | 4.8% | 0.0% |
| Blackrock, Inc. | $48.8M | 2.2M | 4.2% | ▲ 16.7% |
| Vanguard Capital Management LLC | $42.3M | 1.9M | 3.7% | ▲ 6.5% |
| Millennium Management LLC | $37.8M | 1.7M | 3.3% | ▲ 56.2% |
| Loomis Sayles & Co L P | $35.1M | 1.6M | 3.0% | ▼ 6.7% |
| D. E. Shaw & Co., Inc. | $26.4M | 1.2M | 2.3% | ▲ 675.6% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Omada Health, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Duffy Sean P. Chief Executive Officer | October 1, 2026 | Sell pre-set plan | 4,314 | $20.90 | $90,163 |
| Duffy Sean P. Chief Executive Officer | October 1, 2026 | Sell pre-set plan | 12,944 | $20.61 | $266,753 |
| Shao Wei-Li President | September 10, 2026 | Sell pre-set plan | 400 | $22.53 | $9,012 |
| Shao Wei-Li President | September 10, 2026 | Sell pre-set plan | 3,636 | $21.78 | $79,192 |
| Cook Steven L. Chief Financial Officer | September 10, 2026 | Sell pre-set plan | 600 | $22.52 | $13,512 |
| Cook Steven L. Chief Financial Officer | September 10, 2026 | Sell pre-set plan | 6,200 | $21.80 | $135,160 |
| Duffy Sean P. Chief Executive Officer | September 10, 2026 | Sell pre-set plan | 1,400 | $22.59 | $31,626 |
| Duffy Sean P. Chief Executive Officer | September 10, 2026 | Sell pre-set plan | 13,560 | $21.80 | $295,608 |
| Gracey Craig Chief Accounting Officer | September 9, 2026 | Sell pre-set plan | 644 | $21.73 | $13,994 |
| Duffy Sean P. Chief Executive Officer | September 1, 2026 | Sell pre-set plan | 3,695 | $24.27 | $89,678 |
| Duffy Sean P. Chief Executive Officer | September 1, 2026 | Sell pre-set plan | 4,933 | $23.13 | $114,100 |
| Duffy Sean P. Chief Executive Officer | September 1, 2026 | Sell pre-set plan | 5,600 | $24.27 | $135,912 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
